-- Wedbush Securities周三发布的一份报告指出，罗技国际（LOGI）在第四财季展现了稳健的运营模式，其在产品创新、成本控制和供应链优化方面的强劲执行力，推动了毛利率和营业利润率的超预期增长。 报告称，该公司正持续推进其战略重点，包括拓展B2B业务、提升中国市场份额、重振视频协作业务，以及巩固其在个人工作空间解决方案领域的领先地位。 Wedbush分析师表示，尽管PC出货量疲软且零部件成本上涨，罗技仍通过新产品和改进营销策略提升了平均售价，其中G Pro X2 Superstrike的强劲需求凸显了其高端产品和游戏业务的增长。 分析师指出，罗技在PC市场拥有巨大的“空白市场”机遇，且升级渗透率较低，因此，改进营销策略有望推动增长，而净现金流则足以支持其股票回购、分红和收购活动直至2027年。 Wedbush维持对罗技股票的“跑赢大盘”评级，目标价为135美元。
Price: $102.55, Change: $-2.87, Percent Change: -2.72%
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%